Vymada 200mg Tablet – Treatment for Chronic Heart Failure
What is Vymada 200mg Tablet?
Vymada 200mg Tablet is a combination of two medicines (Sacubitril & Valsartan) used to treat chronic heart failure. It helps improve heart function, reduces hospitalization risk, and increases survival rates. It is usually prescribed alongside other heart medications.
Key Benefits:
✔ Improves heart function by relaxing blood vessels
✔ Reduces symptoms like breathlessness, fatigue, and swelling
✔ Lowers risk of complications and hospitalizations
✔ Enhances energy levels and overall well-being
How to Take Vymada 200mg Tablet:
-
Take once or twice daily, as prescribed.
-
Can be taken with or without food, but at a fixed time for best results.
-
Swallow whole—do not crush, chew, or break the tablet.
-
Do not stop suddenly, even if you feel better.
Possible Side Effects:
Most side effects are mild and may include:
-
Low blood pressure (dizziness, lightheadedness)
-
High potassium levels
-
Cough
-
Kidney function changes
Tip: Stand up slowly to avoid dizziness from low blood pressure.
Important Safety Information:
-
Pregnancy: Unsafe—may harm the baby. Consult your doctor.
-
Breastfeeding: Not recommended—potential risk to the infant.
-
Alcohol: Avoid—can worsen dizziness and blood pressure drops.
-
Driving: Use caution—may cause drowsiness or blurred vision.
-
Kidney/Liver Disease: Dose adjustments may be needed—consult your doctor.
How It Works:
Vymada combines Sacubitril (a neprilysin inhibitor) and Valsartan (an ARB) to:
✔ Relax blood vessels for easier blood flow
✔ Reduce fluid retention
✔ Improve heart efficiency
Missed a Dose?
-
Take it as soon as you remember.
-
If close to the next dose, skip the missed dose.
-
Do not double the dose.
Lifestyle Tips for Heart Failure:
-
Follow a low-salt, heart-healthy diet.
-
Stay physically active as advised by your doctor.
-
Monitor blood pressure & kidney function regularly.
Always take as prescribed and inform your doctor of any other medications you are using.
Reviews
There are no reviews yet.